Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q02078
UPID:
MEF2A_HUMAN
Alternative names:
Serum response factor-like protein 1
Alternative UPACC:
Q02078; B4DFQ7; F6XG23; O43814; Q14223; Q14224; Q59GX4; Q7Z6C9; Q96D14
Background:
Myocyte-specific enhancer factor 2A (MEF2A), also known as Serum response factor-like protein 1, plays a pivotal role in muscle-specific gene regulation, growth factor-induced gene activation, and neuronal differentiation. It binds to the MEF2 element, influencing skeletal and cardiac muscle development, neuronal survival, and synaptic differentiation through diverse signaling pathways, including p38 MAPK.
Therapeutic significance:
MEF2A's involvement in coronary artery disease, autosomal dominant, 1, underscores its potential as a therapeutic target. Understanding the role of MEF2A could open doors to potential therapeutic strategies for heart diseases and neuronal disorders.